Advertisement
Screener

Revolution Medicines, Inc. (RVMD) Lessee, Operating Lease, Liability, to be Paid, Year One

2.8 / 5 stars · 68/120 Roast Me

Revolution Medicines, Inc. Lessee, Operating Lease, Liability, to be Paid, Year One

Revolution Medicines, Inc. (RVMD) had Lessee, Operating Lease, Liability, to be Paid, Year One of $20.21 million as of 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Notes › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths · last filed 2026-08-05

  • 2026-06-30: Lessee, Operating Lease, Liability, to be Paid, Year One $20.21M.
  • 2026-03-31: Lessee, Operating Lease, Liability, to be Paid, Year One $20.21M.
  • 2025-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $21.04M.
  • 2025-09-30: Lessee, Operating Lease, Liability, to be Paid, Year One $19.61M.
Period endLessee, Operating Lease, Liability, to be Paid, Year One
2026-06-30$20.21M
10-Q · filed 2026-08-05
2026-03-31$20.21M
10-Q · filed 2026-05-06
2025-12-31$21.04M
10-K · filed 2026-02-25
2025-09-30$19.61M
10-Q · filed 2025-11-05
2025-06-30$17.05M
10-Q · filed 2025-08-06
2025-03-31$17.05M
10-Q · filed 2025-05-07
2024-12-31$18.07M
10-K · filed 2025-02-26
2024-09-30$10.48M
10-Q · filed 2024-11-06
2024-06-30$10.48M
10-Q · filed 2024-08-07
2024-03-31$10.48M
10-Q · filed 2024-05-08
2023-12-31$7.77M
10-K · filed 2024-02-26
2023-09-30$7.10M
10-Q · filed 2023-11-06
2023-06-30$7.10M
10-Q · filed 2023-08-08
2023-03-31$7.10M
10-Q · filed 2023-05-08
2022-12-31$6.96M
10-K · filed 2023-02-27
2022-09-30$6.96M
10-Q · filed 2022-11-07
2022-06-30$6.96M
10-Q · filed 2022-08-09
2022-03-31$6.96M
10-Q · filed 2022-05-09
2021-12-31$7.61M
10-K · filed 2022-02-28
2021-09-30$5.14M
10-Q · filed 2021-11-10
2021-06-30$5.14M
10-Q · filed 2021-08-11
2021-03-31$5.14M
10-Q · filed 2021-05-10
2020-12-31$4.38M
10-K · filed 2021-03-02
2020-09-30$4.38M
10-Q · filed 2020-11-12
2020-06-30$4.38M
10-Q · filed 2020-08-10

Similar stocks

Stock NameCountryMarket CapPE Ratio
BIOGEN INC. (BIIB)United States$33.427B19.60
EXELIXIS, INC. (EXEL)United States$14.358B16.15
NEUROCRINE BIOSCIENCES INC (NBIX)United States$14.131B24.25
HALOZYME THERAPEUTICS, INC. (HALO)United States$13.083B21.59
Twist Bioscience Corp (TWST)United States$11.540B-47.21
BIO-TECHNE Corp (TECH)United States$11.379B74.68
REPLIGEN CORP (RGEN)United States$10.755B185.31
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29